Oral suspensions of spironolactone, hydrochlorothiazide and captopril: Microbiological stability study and clinical use review;Évaluation de suspensions orales pédiatriques de spironolactone, hydrochlorothiazide et captopril: Stabilité microbiologique et revue d'utilisation clinique

Journal de Pharmacie Clinique

Volumn 24, Issue 1, 2005, Pages 23-29

  Fajolle, V ^a   Dujols, C ^a   Darbord, J C ^b   Brion, F ^a   Rieutord, A ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b AGEPS   (France)

Author keywords

Hydrochlorothiazide; Ora Plus ; Ora Sweet ; Oral suspensions; Pediatrics; Spironolactone

Indexed keywords

CAPTOPRIL; EXCIPIENT; HYDROCHLOROTHIAZIDE; ORA PLUS; ORA SWEET; SPIRONOLACTONE;

DRUG CAPSULE; DRUG INDICATION; DRUG SAFETY; DRUG STABILITY; HEART FAILURE; HUMAN; INTENSIVE CARE; MICROBIAL CONTAMINATION; PALATABILITY; REVIEW; WATER RETENTION;

EID: 16344393022     PISSN: 02911981     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Brion F, Pelletier V. La Commission du médicament et l'enfant malade à l'AP-HP. Le bulletin du médicament 1996; 2: 1.
2. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off label drugs on peadiatric wards: a prospective study. Acta Paediatr 1999; 88: 965-8.
3. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. Br Med J 2000; 320: 79-82.
4. Fontan JE, Combeau D, Brion F. Pediatric drug preparations in French hospitals. Pediatric group of French clinical pharmacy society. Arch Pediatr 2000; 7-8: 825-32.
5. Dupont C, Rieutord A, Dufour A, Brion F. Administration d'injectables par voie orale: une alternative pour la pédiatrie? 10° congrès national de pharmacie clinique. Montpellier, 2002.
6. Woods DJ. Extemporaneous formulations. Problems and solutions. Peadiatr Perin Drug Ther 1997; 1: 25-8.
7. Nahata M. Pediatric drug formulations: challenges and solutions. Ann Pharmacother 1999; 33: 247-9.
8. Allen LV, Erickson MA. Stability of labetolol hydrochloride, metoprolol tartrate, verapomil hydrochloride, and spironolactone with nydrochlorothiazide in extemporaneously compounded oral liquids. Am J Health Syst Pharm 1996; 53: 2304-9.
9. Allen LV Jr, Erickson MA 3rd. Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. Am J Health Syst Pharm 1996; 53: 2179-84.
10. e edition. Strasbourg: DEQM, 2002.
11. Bernheim C. Problèmes posés par l'adaptation d'une forme médicamenteuse ô l'usage pédiatrique. Thérapie 1989; 44: 145-50.
12. Alon US, Scagliotti D, Garola RE. Nephrocalcinosis and nephrolithiasis in infants with congestive heart failure treated with furosemide. J Pediatr 1994; 125: 149-51.
13. e edition Hudson: Lexi-comp Inc. 2001.
14. Anonyme. Healthcare series 121. Healthcare micromedex.com. Greenwood: Thomson healthcare, 2004.
15. Anonyme. Medecines for children. Première ed. Londres: Royal College of paediatrics and child health, 2001.
16. Anonyme. Dictionnaire Vidal. Paris: OVP Editions du Vidal, 2004.
17. Anonyme. Better Medicines for children. Bruxelles: EFPIA, 2002.